Sei Investments Co. Makes New Investment in Corvus Pharmaceuticals, Inc. $CRVS

Sei Investments Co. bought a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 60,848 shares of the company’s stock, valued at approximately $890,000.

A number of other hedge funds and other institutional investors have also modified their holdings of CRVS. Orbimed Advisors LLC raised its holdings in shares of Corvus Pharmaceuticals by 3.2% during the 2nd quarter. Orbimed Advisors LLC now owns 7,165,006 shares of the company’s stock worth $28,660,000 after acquiring an additional 221,352 shares during the period. Vanguard Group Inc. grew its holdings in shares of Corvus Pharmaceuticals by 5.8% in the third quarter. Vanguard Group Inc. now owns 3,471,925 shares of the company’s stock valued at $25,588,000 after purchasing an additional 191,216 shares during the period. State Street Corp grew its holdings in shares of Corvus Pharmaceuticals by 177.1% in the fourth quarter. State Street Corp now owns 2,788,223 shares of the company’s stock valued at $21,469,000 after purchasing an additional 1,781,904 shares during the period. MPM Bioimpact LLC acquired a new stake in Corvus Pharmaceuticals during the fourth quarter worth about $21,126,000. Finally, Geode Capital Management LLC increased its position in Corvus Pharmaceuticals by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 1,473,026 shares of the company’s stock worth $11,345,000 after purchasing an additional 16,498 shares during the last quarter. 46.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Corvus Pharmaceuticals

In related news, Director David Scott Moore purchased 21,700 shares of Corvus Pharmaceuticals stock in a transaction dated Thursday, June 11th. The shares were acquired at an average cost of $11.53 per share, with a total value of $250,201.00. Following the purchase, the director owned 21,700 shares of the company’s stock, valued at approximately $250,201. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 19.70% of the stock is currently owned by corporate insiders.

Corvus Pharmaceuticals Trading Up 0.6%

Shares of NASDAQ:CRVS opened at $15.14 on Friday. The business has a 50-day moving average price of $13.64 and a 200 day moving average price of $15.14. The company has a market capitalization of $1.27 billion, a price-to-earnings ratio of -24.82 and a beta of 0.87. Corvus Pharmaceuticals, Inc. has a 12-month low of $4.70 and a 12-month high of $26.95.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.03). As a group, equities research analysts predict that Corvus Pharmaceuticals, Inc. will post -0.79 earnings per share for the current fiscal year.

More Corvus Pharmaceuticals News

Here are the key news stories impacting Corvus Pharmaceuticals this week:

• Positive Sentiment: An independent analysis examines soquelitinib’s clinical science, commercial market opportunity and fair value, keeping attention focused on the potential upside from Corvus’s lead program. The stock has increased from its 52-week low, suggesting investors continue to assign meaningful value to the drug’s development prospects. Corvus: Evaluating Soquelitinib’s Science, Market Reach, And Fair Value
• Neutral Sentiment: HC Wainwright issued a new FY2030 earnings forecast for Corvus. The article does not provide the estimate, but the long-range projection indicates analysts are continuing to model the company’s path toward commercialization and profitability. FY2030 Earnings Forecast for CRVS Issued By HC Wainwright
• Negative Sentiment: HC Wainwright lowered EPS estimates across multiple periods: FY2026 to a loss of $0.83 from $0.66, FY2027 to a loss of $0.80 from $0.63, FY2028 to a loss of $0.37 from $0.25, and FY2029 to a loss of $0.01 from a profit of $0.07. Quarterly estimates were also reduced, including Q3 2026 to a loss of $0.23 from $0.17 and Q1–Q4 2027 to losses ranging from $0.16 to $0.24 per share. These revisions imply slower progress toward profitability and could pressure sentiment. HC Wainwright Earnings Estimate Revisions for Corvus Pharmaceuticals

Wall Street Analyst Weigh In

CRVS has been the topic of several recent analyst reports. LADENBURG THALM/SH SH upgraded shares of Corvus Pharmaceuticals to a “strong-buy” rating in a report on Thursday, July 30th. Weiss Ratings upgraded shares of Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. Wall Street Zen downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, The Goldman Sachs Group initiated coverage on shares of Corvus Pharmaceuticals in a research report on Friday, April 17th. They set a “buy” rating and a $40.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $33.33.

Corvus Pharmaceuticals Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.